NCT05438420 2026-02-24Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsQurient Co., Ltd.Phase 1/2 Active not recruiting120 enrolled
NCT05070247 2026-01-22A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsTakedaPhase 1/2 Terminated61 enrolled 29 charts